SURMOUNT-4 enrolled 783 adults without diabetes into a 36-week open-label tirzepatide lead-in
However, ipamorelin has a distinct advantage over other ghrelin mimetics
Participants starting with an average weight of 113kg achieved: 20.7% weight loss with the 7.2mg weekly regimen 17.5% weight loss with 2.4mg once weekly 2.4% weight loss with placebo More patients reached substantial weight loss milestones on the higher weekly dose
Kekessie I, Wegner K, Martinez I, Kopach ME, White TD, Tom JK, et al
Still, tirzepatide also targets GIP (glucose-dependent insulinotropic peptide) receptors, potentially offering improved blood sugar control compared to Ozempic, which only targets GLP-1 receptors
Additionally, In S